Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04531189 · ClinicalTrials.gov registry record
Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 16
- Enrollment target
NCT04531189: Completed study, sponsored by Ultragenyx Pharmaceutical.
NCT04531189 is a clinical trial that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04531189 has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the relevance and appropriateness of outcome assessments, including biomarkers, within the Wilson disease population to inform study design and endpoint selection for future clinical studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2022-03-25 |
What the finished NCT04531189 record still lists
NCT04531189 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04531189 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04531189 about?
NCT04531189 is a clinical study titled "Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease". The primary objective of the study is to determine the relevance and appropriateness of outcome assessments, including biomarkers, within the Wilson disease population to inform study design and endpoint selection for future clinical studies.
What is the current status of trial NCT04531189?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2020-12-11. Estimated completion is 2022-03-25.
Who is sponsoring clinical trial NCT04531189?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI